
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Wailea, Hawaii - Compliance with allergen avoidance may seem like quite a challenge, even to patients with limited allergies. The Contact Allergen Replacement Database (CARD) aims to level the playing field.